Biotech Values

[DewDiligence]

BMY—CHMP approves Opdivo-plus-low-dose-Yervoy in first-line RCC, regardless of PD-L1 status:

https://www.businesswire.com/news/home/20181115005934/en/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-Recommending

Formal approval the EC Commission will follow in 2-3 months.

The CHMP decision is based on the CHECKMATE-214 study, in which the OS HR in the overall trial was 0.63 for Opdivo/Yervoy vs Sutent (#msg-136010123). The OS HR was 0.73 in PD-L1-negative patients and was 0.45 in PD-L1-positive patients.

p.s. CHECKMATE-214 has nothing whatsoever to do with NKTR-214!